114804-77-2

Upstream product

• 124-38-9 carbon dioxide 
• 2234-45-9 6-benzyloxy-2-bromonaphthalene 
• 17295-11-3 methyl 6-hydroxynaphthalene-2-carboxylate 
• 114804-76-1 6-benzyloxynaphthalene-2-carboxylic acid methyl ester 
• 100-39-0 benzyl bromide 
• 16712-64-4 6-Hydroxy-2-naphthoic acid 
• 15231-91-1 6-bromo-naphthalen-2-ol 
• 66217-29-6 6-(benzyloxy)-2-cyanonaphthalene 
• 98256-93-0 6-Benzyloxy-naphthalene-2-carboxylic Acid Benzyl Ester 

Downstream Products

• 114804-76-1 6-benzyloxynaphthalene-2-carboxylic acid methyl ester 
• 187748-29-4 1'-methylethyl 2-benzyloxy-6-naphthoate 
• 114804-78-3 S(+)-1-Methylheptyl 6-benzyloxy-2-naphthoate 
• 122179-30-0 2-benzyloxynaphthalene-6-carboxylic acid chloride 
• 1606979-39-8 C₃₆H₄₆O₃ 
• 17295-11-3 methyl 6-hydroxynaphthalene-2-carboxylate 
• 301298-99-7 2-Benzyloxy-6-isocyanato-naphthalene 
• 160535-03-5 (R)-1-(Trifluoromethyl)heptyl 6-benzyloxy-2-naphthoate 

Relevant academic research and scientific papers

6-benzyloxyimino-2-naphthoic acid manufacturing method (by machine translation)

PROBLEM TO BE SOLVED: reducing the formation of byproducts, high yield and purity by 6-benzyloxyimino-2-naphthoic acid. SOLUTION: 6-hydroxy-2-naphthoic acid, 6-benzyloxyimino-2-naphthoic acid benzylsuccinic (ester ether body) is generated, by hydrolysis,

2,2'-Binaphthalene Ester Chiral Dopants for Cholesteric Liquid Crystal Displays

A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C═O)R9, —(C═O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Structure-activity relationships for vitamin D3-based aromatic a-ring analogues as hedgehog pathway inhibitors

A structure-activity relationship study for a series of vitamin D3-based (VD3) analogues that incorporate aromatic A-ring mimics with varying functionality has provided key insight into scaffold features that result in potent, selective Hedgehog (Hh) pathway inhibition. Three analogue subclasses containing (1) a single substitution at the ortho or para position of the aromatic A-ring, (2) a heteroaryl or biaryl moiety, or (3) multiple substituents on the aromatic A-ring were prepared and evaluated. Aromatic A-ring mimics incorporating either single or multiple hydrophilic moieties on a six-membered ring inhibited the Hh pathway in both Hh-dependent mouse embryonic fibroblasts and cultured cancer cells (IC50 values 0.74-10 μM). Preliminary studies were conducted to probe the cellular mechanisms through which VD3 and 5, the most active analogue, inhibit Hh signaling. These studies suggested that the anti-Hh activity of VD3 is primarily attributed to the vitamin D receptor, whereas 5 affects Hh inhibition through a separate mechanism.

Tetraoxybiphenyl Ester Chiral Dopants for Cholesteric Liquid Crystal Displays

A liquid crystal composition comprising a chiral dopant compound represented by the following formula: wherein: R1, R2 are independently aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl, alkaryl or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 and R4 are independently hydrogen, halogen, cyano, alkoxy, NHCOR7, NHSO2R7, COOR7, OCOR7, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl, alkaryl or heterocyclic all either substituted or unsubstituted, or combine with either R1 or R2 to form a carbocylic or heterocyclic ring; R5 and R6 are independently hydrogen, CH2, CH, alkyl or aryl either substituted or unsubstituted, COOR7, or combine with L to form a carbocyclic or heterocyclic ring; R7 is aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted; L is the non-metallic elements required to form a carbocyclic or heterocyclic ring, or a single bond or a double bond; m is 1-3; n is 0-12.

NORVALINE DERIVATIVE AND METHOD FOR PREPARATION THEREOF

Norvaline derivative of the formula [I] or pharmaceutically acceptable salt thereof, method for preparing the same, pharmaceutical composition containing the same, and use of said compound for inhibiting transporting activity of glycine transporter type 2 (GlyT2). [wherein X is -CH2-, -O-, -S- or single bond; Ar is optionally substituted aryl or lower cycloalkyl; n is 0 to 2; R1 and R2 are (i) each is hydrogen or lower alkyl; (ii) R1 and R2 are combined to form lower alkylene; or (iii) R1 is hydrogen or lower alkyl and R2 is combined with R4 or R6 to form lower alkylene; R3 and R4 are (i) each is hydrogen or lower alkyl; (ii) R3 and R4 are combined to form lower alkylene; or (iii) R3 is hydrogen or lower alkyl and R4 is combined with R2 or R6 to form lower alkylene; R is or -OR7; R 5 and R6 are (i) each is optionally substituted lower alkyl, or hydrogen; (ii) R5 and R6 are combined to form aliphatic 5- to 6-membered heterocyclic group; or (iii) R5 is optionally substituted lower alkyl or hydrogen and R6 is combined with R2 or R4 to form lower alkylene; R7 is lower alkyl.

2-NAPHTAMIDE DERIVATIVES

The present invention relates to 2-naphthamides, which are useful as an active ingredient of pharmaceutical preparations. The 2-naphthamides of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor activity. Such diseases include urological diseases or disorder as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benign prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since the disease is also alleviated by treatment with an IP receptor antagonist.

Synthesis of a AT base pair model in DNA and determination of hydrogen bonding strength on the formation of base triplet T:AT in CDCl3

A molecular model has been synthesized to determine the hydrogen- bonding strength between AT and T in the base triplet, T:AT. A strong preference (>95%) of Watson-Crick mode along with 91% hydrogen-bonded conformation is observed in the model compound. The association constants of the AT model with 1-propyluracil and glutarimide are 15 M-1 and 5.2 M-1, respectively, in CDCl3 at 296 ± 0.5 K. Negative cooperativity by pre- existing hydrogen bonds might be involved in the intermolecular binding events.

Multichromophoric cyclodextrins. 4. Light conversion by antenna effect

A water soluble β-cyclodextrin (CD-NA) bearing seven naphthoyl chromophores forms very stable 1:1 complexes with a merocyanine laser dye DCM-OH (4-(dicyanomethylene)-2-methyl-6-(p-(bis(hydroxyethyl)amino)-styryl)-4 H-pyran). The antenna effect, i.e. energ

Synthesis and Thermal Properties of Antiferroelectric Liquid Crystals Having Phenylalkanoate and Phenylalkenoate Moieties

Novel antiferroelectric liquid crystals having phenylalkanoate and phenylalkenoate moieties were synthesized and their mesomorphic properties were studied. 4-ethyl>phenyl 4'-decyloxybiphenyl-4-carboxylate 1b exhibi

Optically active naphthalene compounds and liquid crystal materials and devices incorporating them

Optically active naphthalene compounds having the formula: STR1 in which X and Y are selected from combinations (a), (b) and (c): (a) X is C1-10 alkyl or alkoxy and Y is C4-16 optically active alkyl, (b) X is C1-10 alkyl o